Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Gains Rights to Provide Pathology's Miscarriage Tests

NEW YORK (GenomeWeb News) – CombiMatrix said today that Pathology has chosen it to serve as the exclusive provider of Pathology's chromosomal microarray tests for the products of conception testing market in the US.

The deal expands an earlier strategic partnership between the firms forged late last year that provided Pathology with the right to market and distribute CombiMatrix's microarray tests in California and Nevada, as well as St. Louis and Chicago. Products of conception testing is also called miscarriage testing and is a subset of the prenatal testing market.

"We believe this market is going to continue to expand as our physician customers and their patients realize the importance of microarray testing in helping to identify the causes of miscarriages and how that information may assist in future pregnancies," Pathology President and CEO Vicki DiFrancesco said in a statement.

CombiMatrix President and CEO Mark McDonough added that the expansion of the firms' earlier deal "underscores the rapidly expanding importance of microarray testing and the value our team brings to Pathology in terms of operational and analytical support." He said that the deal with Pathology "allows us to extend our customer base of Ob/Gyns and provides us with additional marketing and distribution support."

Financial and other terms were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.